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ABSTRACT
Background. Exercise interventions designed to improve physical function and reduce sedentary behaviour in haemodialysis
(HD) patients might improve exercise capacity, reduce fatigue and lead to improved quality of life (QOL). The PrEscription of
intraDialytic exercise to improve quAlity of Life study aimed to evaluate the effectiveness of a 6-month intradialytic
exercise programme on QOL and physical function, compared with usual care for patients on HD in the UK.
Methods. We conducted a prospective, pragmatic multicentre randomized controlled trial in 335 HD patients and randomly
(1:1) assigned them to either (i) intradialytic exercise training plus usual care maintenance HD or (ii) usual care
maintenance HD. The primary outcome of the study was the change in Kidney Disease Quality of Life Short Form (KDQOL-
SF 1.3) Physical Component Score between baseline and 6 months. Additional secondary outcomes included changes in
peak aerobic capacity, physical fitness, habitual physical activity levels and falls (International Physical Activity
Questionnaire, Duke’s Activity Status Index and Tinetti Falls Efficacy Scale), QOL and symptom burden assessments (EQ5D),
arterial stiffness (pulse wave velocity), anthropometric measures, resting blood pressure, clinical chemistry, safety and
harms associated with the intervention, hospitalizations and cost-effectiveness. A nested qualitative study investigated the
experience and acceptability of the intervention for both participants and members of the renal health care team.
Results. At baseline assessment, 62.4% of the randomized cohort were male, the median age was 59.3 years and 50.4% were
white. Prior cerebrovascular events and myocardial infarction were present in 8 and 12% of the cohort, respectively, 77.9%
of patients had hypertension and 39.4% had diabetes. Baseline clinical characteristics and laboratory data for the
randomized cohort were generally concordant with data from the UK Renal Registry.
Conclusion. The results from this study will address a significant knowledge gap in the prescription of exercise interventions
for patients receiving maintenance HD therapy and inform the development of intradialytic exercise programmes both
nationally and internationally.
Trial Registration. ISRCTN N83508514; registered on 17 December 2014.
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INTRODUCTION
Haemodialysis (HD) is a major treatment option for patients
with end-stage kidney failure. Over 27 000 patients receive dial-
ysis for chronic kidney disease (CKD) in the UK and 80% of these
are treated with HD [1]. Improved dialysis techniques and man-
agement of co-existing disease have made HD more tolerable
and many new patients can anticipate a longer life expectancy
[2], although not always with a good quality of life (QOL).
Both physical inactivity and impaired physical function are
strongly associated with increased morbidity, mortality and re-
duced QOL in patients on HD [2, 3]. Reduced QOL is also inde-
pendently associated with mortality in patients on HD. Reports
indicate that 36-item Short Form Health Survey (SF-36) QOL-
Physical Component Scores (PCSs) of <25 were associated with
a 93% increased risk of death and a 56% increased risk of hospi-
talization in HD patients, while a 10-point decrease in the PCS
translated into a 25% increased risk of death within 2 years [4].
Conversely, a 1-point increase in the PCS was associated with a
3.5% improvement in the odds of death [5]. Interventions
designed to increase physical function and reduce sedentary be-
haviour in HD patients may mitigate CVD risk, improve physical
functioning, improve fitness for potential future kidney trans-
plantation, lower levels of fatigue and in turn lead to improved
QOL. A study by Painter et al. [6] reported an average 4-point in-
crease in the PCS in the intervention group (in-centre intradia-
lytic cycling or individualized home exercise programme), and
an average 6-point decrease in the score in the non-
intervention group. DeOreo [7] reported that for every increase
in PCS of 5 points, there is an approximately 10% increase in the
probability of survival.
Evidence from several systematic reviews [8–21] indicates
that a range of exercise training interventions show potential to
improve exercise capacity and physical function in patients
with dialysis-dependent CKD. The greatest effects were
reported after 6 months of exercise and were associated with
both supervised and higher intensities of exercise. However,
most of the studies reviewed were small trials, many of which
were not methodologically robust, and non-intradialytic inter-
ventions were occasionally included in the evidence synthesis
[15]. Relatively few of the reviewed studies on intradialytic exer-
cise training were appropriately powered to detect QOL out-
comes, and none included a cost-effectiveness analysis.
Moreover, adverse events in the published literature were only
recorded in a minority of studies [16] or were poorly reported
[15]. A recent systematic review [21] on intradialytic exercise
training suggests that aerobic and resistance exercise pro-
grammes, delivered alone, can improve aerobic capacity but
that a combination of both can improve a greater range of out-
comes, including exercise capacity, depression and some ele-
ments of QOL. In contrast, a recent systematic review by Young
et al. [17] indicated that there was insufficient evidence demon-
strating whether cycling exercise during HD improves patient
outcomes. The recommendations emerging from these system-
atic reviews indicated the need for (i) high-quality, adequately
powered randomized controlled trials (RCTs) of intradialytic ex-
ercise and (ii) routine collection and reporting of adverse event
data associated with participation in these trials. The genera-
tion of this information may help to more fully identify recom-
mendations for an exercise delivery pathway for HD patients
and ultimately its clinical implementation [20].
The PrEscription of intraDialytic exercise to improve quAlity
of Life (PEDAL) study was designed in response to a National
Institute for Health Research (NIHR) commissioned call to
evaluate the clinical benefit and cost-effectiveness of exercise
during HD (intradialytic exercise) in patients with end-stage kid-
ney disease. At the time of planning and developing the PEDAL
study (2012), there was extremely limited evidence on the effec-
tiveness of intradialytic cycling on patient-centred outcomes
such as QOL indices. In CKD Stages 2–5, overall quality of life in-
dices was improved with exercise training. Improved scores in
the self-reported physical function sub-scores of the question-
naires used appeared to be the main drivers for the overall im-
provement. Other elements of QOL such as vitality, social
function and general health did not show a systematic change
[8]. Short-term (2–6 months) structured and supervised
moderate-intensity aerobic training programmes (mainly cy-
cling) have been reported to induce a systematic and large im-
provement in cardiorespiratory fitness [volume of oxygen
consumption (VO2peak)] of 17–50%, with an overall mean differ-
ence between treatment and control groups of 5.22 mL/kg/min.
Such improvements exceed the clinically important criterion of
1 MET (3.5 mL/kg/min). Thus, we utilized the evidence base pro-
moting intradialytic cycling for improved cardiorespiratory fit-
ness to investigate whether the physiological benefits derived
from cycling, could extend to perceived enhanced QOL.
Furthermore, as inconsistent improvements have been noted
for objectively measured functional capacity indices (walking
speed/distance, sit-to-stand performance) from previous intra-
dialytic cycling studies, we chose to evaluate key secondary out-
come measures of objective physical function.
The rationale for intradialytic exercise is both intuitively and
pragmatically appealing as the environment of unit-based HD
provides a platform for longer term sustainable implementation
of exercise rehabilitation programmes, and thus could promote
exercise-enhancing behaviours in HD patients. The pre-existing
need for patients to attend for standard thrice weekly, 4 h-long
HD sessions provides a practical opportunity to deliver a struc-
tured and supervised rehabilitation programme with an en-
hanced potential for participation, associated with a
substantially reduced patient burden in terms of time, effort
and travel costs.
MATERIALS ANDMETHODS
Primary objective
The primary objective of this trial was to determine, in compari-
son with usual care, whether usual care augmented by intradia-
lytic exercise training for a period of 6 months improved The
Kidney Disease Quality of Life Short Form (KDQOL-SF 1.3)
Physical Component Score (PCS) in CKD Stage 5 patients receiv-
ing maintenance HD.
Secondary objective
Secondary objectives were to determine, in comparison with
usual care, whether usual care augmented by intradialytic exer-
cise training improved:
Physical function and physical activity (PA) outcomes:
• Peak aerobic capacity
• Physical fitness indicators
• Gait speed
• Lower limb strength
Clinical measures:
• Resting blood pressure
• Haemoglobin, serum phosphate, parathyroid hormone
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• Arterial stiffness (pulse wave velocity)
Anthropometric measures:
• Body mass index (BMI)
• Waist and hip circumference
Patient-reported outcomes:
• Quality of life and symptom burden assessments (EQ5D)
• Habitual PA levels (International Physical Activity
Questionnaire)
• Duke’s Activity Status Index
• Falls confidence (Tinetti Falls Efficacy Scale)
Economic analysis of cost-effectiveness:
• Quality-adjusted life years (QALYs) will be derived from
EQ5D
• Resource use associated with physiotherapy assistant time
• Resource use associated with delivery of exercise
programme
• Equipment costs
• Hospital admissions and medication use will be recorded
(with consent) from the patient’s clinical records
Qualitative study:
• A nested qualitative study investigated the experience and
acceptability of the intervention for both participants and
members of the renal care team
Design, setting and participants
This was a prospective, pragmatic multicentre RCT with blinded
outcome assessment. The flow of participants through the trial
is summarized in Table 1. We aimed to recruit prevalent adult
patients (aged >18 years), treated as outpatients, undergoing in-
centre (hospital unit, satellite unit) maintenance HD. Participants
were recruited from 10 sites in five ‘regions’ spread across the
UK. The research sites selected were broadly representative of
contemporary UK HD units and geographically covered a wide
range of the UK. These centres were selected as they also pro-
vided access to large numbers of prevalent HD patients. London
Fulham Research Ethics Committee approved the protocol (14/
LO/1851; NCT02222402), and the study was prospectively regis-
tered (ISRCTN N83508514). The Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) Checklist is
available in Supplementary data, File S1 of this report.
Recruitment and eligibility
The majority of potential participants for the PEDAL study were
identified during routine HD clinical consultations and concur-
rent evaluation of clinical records to confirm eligibility for par-
ticipation. Patients already established on HD for >3 months
were eligible and easily identified from hospital databases and
dialysis logs. If considered eligible for the study, they were
approached by a member of the renal health care team who dis-
cussed the study and provided them with a Participant
Table 1. Overview of trial schedule
Outcome measure/procedure Screening Baseline 6 months
Informed consent X
Inclusion/exclusion criteria X
Medical history/demographics X
Adverse events recorded X X
Review/record medication X X
Anthropometric measurements
Height X X
Weight X X
BMI X X
Waist-to-hip ratio X X
QOL (and symptom burden) assessments
KDQOL-SF 1.3 questionnaire X X
EQ5D questionnaire X X
Cardiovascular assessments
Resting blood pressure X X
Pulse wave velocity X X
Functional capacity measurements
Peak aerobic capacity (VO2 peak and/or peak power output) X X
Sit-to-stand 60 X X
Functional mobility (10mTUG) X X
DASI Questionnaire X X
Tinetti Falls Efficacy Scale X X
Habitual PA
IPAQ questionnaire X X
Clinical chemistry
Hb X X
Phosphate X X
Parathyroid hormone X X
Medication
ESAs X X
10mTUG, 10 m Timed Up and Go test; ESAs, erythropoiesis-stimulating agents.
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Information Sheet (PIS) with further details to read. After allow-
ing the patient a minimum of 24 h to read and consider the in-
formation in the PIS and to consult with family members, the
research team approached the patient (usually during the next
dialysis session) to answer any questions. If the patient was
agreeable to proceed, an appointment was made for familiariza-
tion and baseline outcome assessment sessions. Written in-
formed consent was obtained by a member of the research
team prior to any study assessments.
Inclusion criteria
Prevalent CKD Stage 5 patients receiving maintenance HD ther-
apy for >3 months, who were male or female, aged >18 years
and who were able to provide written informed consent.
Exclusion criteria
Patients with expected survival on dialysis of <6 months [i.e.
those with severe heart failure (New York Heart Association
3)], patients for whom dialysis withdrawal was being consid-
ered, patients likely to receive a live-donor transplant or trans-
fer to peritoneal dialysis in the period of time, all patients
within 3 months of initiation of HD (patients in this time frame
are generally less clinically stable, many having vascular access
procedures performed and with much higher rates of intercur-
rent events, including death and hospitalization), patients
deemed to be clinically unstable by their treating physician, bi-
lateral lower limb amputations, patients with dementia or se-
vere cognitive impairment and other patients unable to give
informed consent, patients with psychiatric disorders (who are
not treated and stable) and patients who were pregnant.
Randomization and blinding
Randomization was conducted via a centrally controlled web-
based randomization system, run by the Glasgow Clinical Trials
Unit (GCTU). To ensure balanced assignment across critical vari-
ables, a minimization algorithm was employed, taking into ac-
count baseline age, gender and diabetes status. It was
impossible to blind the ‘treating’ physiotherapy assistants or
the participants, and thus the study implemented a blinded
outcome assessment and analysis.
Intervention arms
Intradialytic exercise prescription and training programme. The
intradialytic exercise prescription was based on current PA
guidelines for the elderly [22], and for people with diabetes [23]
and cardiovascular disease [24]. These recommend a minimum
target amount of 1000 kcal per week be expended in PA for
health benefits, with optimal benefits associated with weekly
target PA accumulation of 1500–2000 kcal or at least 150 min/
week at moderate-intensity exercise and at least 2 days a week
of resistance-based training for muscular endurance and
strength gains. As opportunity for structured prescribed exer-
cise was largely restricted to patients’ three HD days, the train-
ing aim was for the patients to accumulate as great a proportion
of this minimum threshold level of 1500 kcal per week via intra-
dialytic exercise, as possible. A target overall volume of exercise
was calculated in EE units (kcal/week) using the FIIT principle
(Frequency, Intensity, Time, Type) and provided for all patients,
with an individualized progression plan towards this goal.
The following progression plan was devised as a general
guide:
Introductory/adoption phase. A minimum cycling duration of
21 min/dialysis session was used as a starting point target
(150 min of moderate-intensity exercise/7 days). By the end of
the first 4 weeks all patients were expected to cycle for 21 min
either in 2 10 min bouts or continuously at the low end of the
moderate exercise intensity range.
The progression requirements were that, by Week 8, all par-
ticipants should be able to cycle for at least 21 min continuously
on the cycle ergometer (63 min/week) at the low end of the mod-
erate exercise intensity range. Minimum target overall volume
of exercise prescription was set at 140 kcal/cycling session.
Progression/adoption phase. This phase is expected to last up to
12–14 weeks. During these weeks, emphasis was given on pro-
gressing exercise stimulus via duration mainly. A reasonable
and achievable exercise target for this group would be a mini-
mum cycling duration of 21–30 min/dialysis session at moder-
ate intensity. Minimum target overall volume of exercise
prescription was set at 1000–1200 kcal/week or 170 kcal/dial-
ysis exercise session.
Behaviour development phase. This phase is expected to last up to
24 weeks. All patients should be able to achieve a target dura-
tion ranging from 30 to 40 min/dialysis session (90–120 min/
week) at moderate to vigorous exercise intensity (55–70% VO2
reserve). Minimum target overall volume of exercise was set at
1500 kcal/week (or 214 kcal/dialysis session) and this would
be achieved via adjustments to duration and intensity.
The prescribed individualized training intensity was derived
from a peak aerobic capacity (VO2peak) assessment, using a 1-
min ramp incremental protocol on a cycle ergometer. New exer-
cise intensity ranges were established at the 3-month follow-up
assessment point. Exercise prescription was set at a workload
corresponding to 40–75% of VO2 reserve. We also made a note of
rate of perceived exertion (RPE), heart rate (HR) and BP
responses corresponding to these ranges of exercise intensity
during the incremental cycle testing protocol and used these in-
dices to guide and monitor progression until the next planned
assessment point (3 months) at which time the exercise pre-
scription was renewed.
Using a modified and custom-made cycle ergometer
(MONARK), aerobic exercise was performed in a semi-
recumbent position, three times per week during the first 2 h of
HD. Exercise duration and intensity were recorded and moni-
tored for each exercise session via exercise diaries. Also, RPE, BP
and HR were recorded during the training sessions. The energy
expenditure goals were deliverable via a progressive increase in
intradialytic cycling from short bouts of 8–10 min in duration to
start with, to 21–40 min or longer, at the prescribed exercise in-
tensity, resulting in 55, 69 and 75%, respectively, of the 1000 kcal
target weekly minimum PA volume being achieved. Twice per
week participants also completed lower extremity muscular
conditioning exercise, using ankle weights, after the aerobic cy-
cling exercise. Physiotherapy assistants (PTA, band 4 Technical
Instructors) were employed in each region to deliver the intra-
dialytic intervention. This role, supervised and quality assured
by a regional coordinator, involved the technical implementa-
tion of the exercise prescription produced by the regional
Research Assistant who was blinded to treatment allocation.
Usual care: HD therapy. Usual care was based on UK Renal
Association Guidelines for haemodialysis [1] and included man-
agement of blood pressure (BP), treatment of anaemia, phos-
phate control and cardiovascular risk mitigation strategies. For
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the purposes of the trial, we specified that usual care, in both
arms of the trial, should allow all of these treatments to con-
tinue unchanged so that we were investigating any additional
benefit of the intradialytic exercise training intervention to
usual care.
Adherence
We attempted to minimize the loss to follow-up in this study by
(i) emphasizing to participants the importance of their atten-
dance at follow-up assessments even if they were no longer
compliant with the intervention, (ii) reducing outcome assess-
ment appointments to a maximum of two non-dialysis day vis-
its, (iii) using a reminder protocol for non-dialysis day
assessment appointments that utilized prompts via the dialysis
unit staff, letters and telephone contact, (iii) providing travel re-
muneration (including, where necessary, taxi costs) and (iv) pro-
vision of training in issues related to compliance for all study
staff who came into contact with the participants.
Assessment outcomes and their measurement
Baseline clinical information and study visits. A summary of
the study schedule is shown in Table 1. Clinical data including
cause of CKD, comorbidities and medications were collected via
participant interviews and reviews of clinical databases and
records at the baseline study visit. Follow-up data collection
was scheduled at 6 months post-randomization. The 6-month
follow-up was chosen as the primary outcome time point as
this has been reported as the optimum duration for the largest
effect sizes following exercise rehabilitation research trials.
Primary outcome
The primary endpoint for this study was the change in KDQOL-
SF 1.3 PCS between baseline and 6 months. The KDQOL-SF 1.3 is
a disease-specific QOL measure. The KDQOL-SF 1.3 question-
naire includes the SF-36 as the generic core plus symptoms/
problems of kidney disease scales. The SF-36 questionnaire has
36 items compiled into eight scales: physical functioning (PF),
role functioning/physical (RP), bodily pain, general health (GH),
vitality (VT), social functioning (SF), role functioning/emotional
(RE) and mental health (MH). These scales are scored from 0 to
100; a higher score is more positive (i.e. less pain or less limita-
tion). Normalized scores representing overall physical function-
ing and mental functioning are calculated from the individual
scales and are presented as the Physical Component Score (PCS)
and the mental component scale. The PCS includes the dimen-
sions of PF, RP, bodily pain, GH, VT and SF.
Key secondary outcomes
QOL. A documented change in the EQ5D from baseline to
6 months was a key QOL secondary outcome.
Peak aerobic capacity. VO2peak was determined by an incre-
mental cycling exercise tolerance protocol. Breath-by-breath
gas exchange was measured using cardiopulmonary exercise
testing equipment calibrated prior to each patient assessment.
The exercise testing protocol started from a 3-min unloaded cy-
cle, followed by ramp increases in resistance of 15 W/min until
one of the following occurred: (i) a plateau in oxygen uptake, (ii)
attainment of respiratory exchange ratio 1.15 or (iii) patient
requested to stop. Average oxygen uptake of the final 20 s of the
test was recorded as the VO2peak (L/min). Electrocardiogram
and HR were continuously monitored, and BP was recorded ev-
ery 1 or 2 min throughout the ramp incremental test. RPE, using
the CR100 RPE scale and angina scale was recorded every min-
ute for safety.
Physical performance tests. Patient physical function was
assessed by the sit-to-stand-60 (STS60) test [25] and the 10-me-
tre timed-up-go (10mTUG) test [26], both of which have been
used as accurate and valid measures of lower leg strength, bal-
ance, coordination, gait speed and physical function in HD
patients.
Anthropometric measures. Measures of height, body mass, BMI
and waist circumference were performed.
Cardiovascular risk. Carotid–femoral pulse wave velocity (PWV)
is considered the gold standard for non-invasive arterial stiff-
ness assessment in clinical practice [27] and has been suggested
as a surrogate cardiovascular endpoint. This was assessed with
the Vicorder system (Skidmore Industries, UK). The Vicorder
system is small, portable, non-invasive and non-operator de-
pendant. In addition, it was available in all centres to ensure
comparability of the data. Conditions for assessment, as stated
by the expert consensus statement by Laurent et al. [27], were
adhered to for all measurements. The measurement protocol by
Hickson et al. [28] was used, mathematically removing the addi-
tional femoral segment from the Vicorder standard protocol to
correct for any inherent bias at high arterial PWV. The average
of three measurements (of 20 consecutive signals) was recorded
at each time point. Resting predialysis BP was assessed.
Physical function questionnaires, PA and fear of falling. Patients
completed the following questionnaires to capture data about
physical activity, activities of daily living and falls: The
International Physical Activity Questionnaire Long Form (IPAQ-
LF) [29], The Duke Activity Status Index (DASI)—a self-reported
12-item questionnaire that assesses activities of daily living
[30]. The Tinetti Falls Efficacy Scale measured fear of falling [31].
Blood tests. Clinical blood tests were collected pre-dialysis and
included haemoglobin (Hb), serum phosphate and parathyroid
hormone.
Medication. Dosages of erythropoiesis-stimulating agents were
recorded.
Safety and monitoring of the intervention. Safety and monitor-
ing data included discontinuation from the exercise interven-
tion and permanent study withdrawals with reasons,
compliance with the exercise programme and adherence to the
exercise prescription and serious adverse events.
All key secondary outcome measures will be reported in the
publication of the primary results.
Other outcomes
Qualitative study. A constructivist phenomenological approach
was used to learn about views and perceptions of participants
and build greater understanding of varied perspectives of both
service users and providers [32, 33]. Focus groups and individual
semi-structured interviews were used as most appropriate to
the stage of the study and location of data collection. Purposive
sampling continued until data saturation was reached and was
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used to ensure varied experiences and viewpoints were repre-
sented, for example, including service users and providers from
different study regions, including people in both study arms
and people with different participation rates and response to
the intervention.
Health economic analysis. QALYs were derived from utility
scores generated using a standard UK algorithm from the EQ5D.
Resource use associated with physiotherapy assistant time and
training (in use of equipment and delivery of personal exercise
programmes per patient) time was recorded prospectively using
timesheets for the intervention group. Equipment costs were
calculated using the annuity method with discounting rates set
as per National Institute for Health and Care Excellence (NICE)
base case. Hospital admissions and medication use were
recorded (with consent) from the patient’s clinical records.
Sample size
Primary outcome: KDQOL-SF 1.3 PCS. A sample size calculation,
based on an assumed difference of 4 points in the PCS score and
a standard deviation (SD) of 10 points as seen in the study by
Painter et al. [6], and conservatively comparing 6-month
KDQOL-SF 1.3 PCS between groups by two-sample t-test (two-
sided 5% significance level), resulted in a sample size of 133
completers per group with 83% power to detect a mean differ-
ence of four points in KDQOL-SF 1.3 PCS. To allow for a 30% loss
to follow-up over 6 months as seen in Phase II trials [23], 190
participants per group were suggested to be randomized. This
sample size calculation did not take into account adjustment
for baseline PCSs. Subsequent analysis of within-trial change in
the PCS from baseline, adjusted for baseline levels and random-
ization minimization variables, suggests that the study will
have 80% power to detect a four-point difference with only 87
participants per group with complete data at baseline and 6-
month follow-up. Likewise, 115 participants per group would be
needed if a zero score is imputed for deaths prior to 6 months.
Key secondary outcome. Analysis of blinded within-trial data
adjusting for baseline levels and randomization minimization
variables suggest that a study of 44 participants per group would
have 90% power to detect the minimum clinically important dif-
ference in peak aerobic capacity of 3.5 mL/kg/min (1 MET).
Statistical analyses
A full statistical analysis plan will be signed off prior to database
lock and study unblinding.
Descriptive statistics of clinical and socio-demographic vari-
ables at baseline are presented split by treatment group.
Primary outcome. The primary outcome measure (change from
baseline to 6 months in KDQOL-SF 1.3 PCS) will be compared be-
tween the control and intervention groups using a normal lin-
ear model adjusting for baseline KDQOL-SF 1.3 PCS and the
randomization minimization variables. The findings will be pre-
sented as the (adjusted) mean difference (95% confidence inter-
val) between the treatment groups. The main analysis will be
carried out on research participants with PCS assessments from
baseline to 6 months. Two sensitivity analyses will also be car-
ried out, first imputing a score of zero for those who die prior to
6 months and secondly, based on all participants with a base-
line PCS using the method of multiple imputation.
Secondary outcomes. Other continuous outcomes will be ana-
lysed as for the primary outcome. The Bonferroni correction
will be applied for multiple comparisons between groups.
Binary outcomes will be compared between treatment
groups using logistic regression models adjusting for baseline
value. The results will be reported as the adjusted odds ratio,
with a 95% confidence interval.
Time-to-event outcomes will be calculated as time from ran-
domization and will be compared between treatment groups us-
ing Cox proportional hazards regression models. The results
will be reported as the adjusted hazard ratio for intervention
versus control, with a 95% confidence interval.
Data involving counts of events will be compared between
treatment groups using negative binomial regression models
adjusting for length of follow-up. The results will be reported as
the adjusted treatment effect, with a 95% confidence interval.
Subgroup analyses. The effect of treatment on the primary out-
come will be compared between those who have an exercise
prescription at baseline (those who have VO2peak at baseline)
and those who do not. This will be done using a linear regres-
sion model predicting the primary outcome from treatment,
whether or not exercise prescription at baseline is available,
and the interaction of both variables, adjusting for minimiza-
tion variables.
Within the intervention group, the primary outcome will be
compared between those who have completed <30% of the
expected exercise sessions, those who have completed 30% but
<50%, those who have completed 50% but <70%, and those
who have completed >70% of the expected exercise sessions.
This will be done using a linear regression model predicting the
primary outcome from the above categories for the expected ex-
ercise sessions completed, adjusting for minimization variables.
The primary outcome will also be assessed comparing the
control group with the three completer groups defined above.
In addition, the relation of percentage of sessions completed
at 6 months follow-up to the primary outcome will be analysed
in two ways:
• As a linear regression predicting the primary outcome from
the percentage of sessions completed at 6 months follow-up,
adjusting for baseline PCS and minimization variables, in
the intervention group only.
• As linear regression predicting primary outcome from the
percentage of sessions completed at 6 months follow-up,
adjusting baseline PCS for minimization variables, in all
patients, setting the percentage of sessions completed to 0
in the control group.
Safety analyses. Discontinuations from the intervention and
permanent study withdrawals and their reasons will be tabu-
lated as will adherence to the exercise prescription. Serious ad-
verse events will be tabulated by system organ class and body
system. The safety analysis is based on collection of and de-
scription of all hospitalizations for any cause whether related,
possibly related or unrelated, and all other reported Serious
Adverse Events (SAEs).
Data monitoring and quality assurance
The trial was coordinated by a Trial Management Group (TMG),
consisting of the Chief Investigator, GCTU Assistant Director
and Senior Clinical Trial Manager and a statistician. The Trial
Manager coordinated the study and was accountable to the
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Chief Investigator. The Central Trial Office (King’s College
Hospital & Glasgow Clinical Trials Unit) provided support to
each site. The Trial Office was responsible for randomization,
collection of data in collaboration with the research coordinator,
data processing and analysis. Publication and dissemination of
the study results will be coordinated by the Trial Office in col-
laboration with the Chief Investigator and Investigators. A Trial
Steering Committee (TSC) was established to oversee the con-
duct and progress of the trial. The study’s funder, National
Institute for Health Research (NIHR) HTA, formally appointed
the chair and members after the nominations from the TMG. A
charter was drawn up to describe membership, roles and re-
sponsibilities of the TSC. The Independent Data Monitoring
Committee was an independent group of experts, consisting of
a nephrologist, physiotherapist, lay member and a statistician,
who monitored patient safety and treatment efficacy data while
the clinical trial was ongoing; the primary mandate of this com-
mittee was to protect patient safety.
Baseline characteristics of randomized participants
Of the 335 randomized patients, 62.4% were male (Table 2). The
median [interquartile range (IQR)] age was 59.3 (48.8–70.5) years.
Half of the randomized population was white and 34.3% was
Black African/Black Caribbean. The mean (SD) weight was 80.5
(20.1) kg and most participants were classified as overweight or
obese [median (IQR) BMI of 27.8 (24.0–32.2) kg/m2]. Thirteen per-
cent reported a musculoskeletal or orthopaedic condition, and
patients had an Hb between 100 and 120 g/dL at baseline.
Prior cardiovascular events and risk factors
A history of major adverse cardiovascular events affected the
minority of participants, reflecting the incident nature of the
population; prior stroke and myocardial infarction were present
in 8 and 12% of the cohort, respectively. A history of heart fail-
ure or peripheral vascular disease was recorded for 4 and 10% of
participants, respectively. At baseline, 78% had hypertension,
39% had diabetes, 21% had hyperlipidaemia and 58% had never
smoked.
Ethics approval and consent to participate
London Fulham Research Ethics Committee approved this pro-
tocol (14/LO/1851). The study was prospectively registered
(ISRCTN N83508514).
Table 2. Baseline characteristics in all randomized participants (intention to treat population)
Characteristic Value N Summary
Age (years) Mean (SD) 335 59.4 (14.7)
Median (Q1, Q3) 59.3 (48.8–70.5)
Gender n (%) Female 335 126 (37.6)
Ethnicity n (%) White 169 (50.4)
n (%) Black Caribbean 47 (14.0)
n (%) Black African 335 68 (20.3)
n (%) South Asian (Indian, Pakistani, Bangladeshi) 39 (11.6)
n (%) Chinese 2 (0.6)
n (%) Other 10 (3.0)
Weight (kg) Mean (SD) 333 80.5 (20.1)
Median (Q1, Q3) 77.5 (66.0–91.7)
BMI (kg/m2) Mean (SD) 333 28.7 (6.7)
Median (Q1, Q3) 27.8 (24.0–32.2)
Smoking n (%) Current 335 42 (12.5)
n (%) Former 98 (29.3)
n (%) Never 195 (58.2)
SBP (mmHg) Mean (SD) 332 136.1 (21.9)
Median (Q1, Q3) 135.0 (121.3–150.8)
DBP (mmHg) Mean (SD) 332 73.6 (14.1)
Median (Q1, Q3) 73.0 (63.3–82.0)
Peripheral vascular disease n (%) Yes 335 11 (3.3)
Diabetes n (%) Yes 335 132 (39.4)
Hypertension n (%) Yes 335 261 (77.9)
Hyperlipidaemia n (%) Yes 335 71 (21.2)
Previous MI n (%) Yes 335 41 (12.2)
Heart failure n (%) Yes 335 32 (9.6)
Cerebrovascular events n (%) Yes 335 26 (7.8)
Cardiovascular conditions n (%) Yes 335 69 (20.6)
Musculoskeletal and orthopaedic condition n (%) Yes 335 43 (12.8)
Hb (g/L) Mean (SD) 320 110.3 (13.5)
Median (Q1, Q3) 110.0 (102.0–119.0)
CRP (mg/L) Mean (SD) 315 14.5 (19.9)
Median (Q1, Q3) 7.0 (3.0–17.1)
URR (%) Mean (SD) 318 71.5 (8.1)
Median (Q1, Q3) 72.7 (67.0–77.0)
Continuous variables are shown as mean (SD) or median (Q1, Q3).
SBP, systolic blood pressure; DBP: diastolic blood pressure; CRP, C-reactive protein; URR, urea reduction ratio; MI, myocardial infarction.
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Availability of data and materials
Findings from the study will be disseminated at national and in-
ternational conferences. All data published from this study will
be available if requested in writing from the chief investigator.
Trial status
The current version is Version 5, 20 June 2019. Recruitment fin-
ished on 31 April 2019. The study completed on 28 February
2020. Trial sponsor: King’s College Hospital, Denmark Hill,
London SE5 9RS, UK.
DISCUSSION
Physical inactivity and impaired physical function are strongly
associated with increased morbidity, mortality and reduced
health-related QOL in HD patients [2, 3]. However, these
patients do not usually receive formal exercise-based rehabilita-
tion as part of routine care. Physical inactivity is a modifiable
risk factor and exercise interventions designed to improve
physical function and reduce sedentary behaviours may im-
prove health-related outcomes and be cost-effective in the lon-
ger term. However, despite the evidence from a number of
systematic reviews on the potential efficacy of exercise training
interventions for patients with dialysis-dependent CKD [8–21],
there remains a pressing need for high-quality evidence from
RCTs in order to evaluate the clinical benefit and cost-
effectiveness of intradialytic exercise. Without this evidence,
there is unlikely to be any traction in the commissioning of rou-
tine exercise-based interventions for patients with dialysis-
dependent CKD, including intradialytic exercise training. In ad-
dition, it is essential that cost-effectiveness information is gen-
erated to aid decision making around the potential value of the
clinical implementation of an exercise delivery pathway for
patients on HD [20].
The primary aim of the PEDAL study was to determine
whether intradialytic exercise training, in comparison with
usual care, improves health-related QOL in CKD Stage 5 patients
receiving maintenance HD therapy. This will be the first large
multicentre RCT that has been appropriately powered to inves-
tigate the effect of intradialytic exercise rehabilitation, delivered
pragmatically by physiotherapy assistants, on health-related
QOL in patients receiving HD therapy.
The baseline demographic data of the PEDAL trial cohort
broadly aligns with the ‘real-world’ dialysis population in
the UK as detailed by the latest data from the UK Renal
Registry [34] and also the Proactive IV irOn Therapy in
hemodiALysis patients (PIVOTAL) trial, a recent large inter-
ventional study conducted in UK renal units [35]. Baseline
age, sex, BMI, BP, diabetes prevalence and the proportion of
current smokers are all similar to UK Renal Registry data
[34]. However, the current study included a larger proportion
of Black African and Black Caribbean participants, and a
lesser proportion of White participants, than what is repre-
sentative of the broader prevalent dialysis population in the
UK. The baseline data are similar to most dialysis popula-
tions worldwide [36–39]. There are some differences in rates
of diabetes prevalence, with lower rates in our patient co-
hort compared with dialysis populations in the USA and
Asia, which may limit application of the results to all other
dialysis populations.
The results of the PEDAL trial will address a significant
knowledge gap in the promotion and prescription of exercise
for patients receiving HD therapy. If the study demonstrates
that the exercise intervention is beneficial, there will be a
strong case for implementation of intradialytic exercise
training for patients with similar inclusion/exclusion criteria
who are receiving HD therapy. The study was ‘open-label’
and that does increase the risk of bias in favour of the inter-
vention. We did however attempt to mitigate this with
blinded assessments. The PEDAL study was deliberately
designed to be a pragmatic intervention that could be imple-
mented with relative ease. There is potential for the results
of the PEDAL study to be realized by patients in participating
trial centres who have equipment and personnel immedi-
ately, and for the results to be used to aid national and inter-
national commissioning of intradialytic exercise training
programmes.
PATIENT CONSENT
Not applicable.
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Supplementary data are available at ckj online.
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